Physician profile
Peter L Shue
NPI 1851578991
$5,255.80
in general payments reported to CMS, 2019-2025
23 companies · $1,005 in 2025
The $1,005 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $71.65 · 2020: $12.90 · 2021: $637 · 2022: $1,012 · 2023: $1,111 · 2024: $1,406 · 2025: $1,005.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,493 · Education: $29.12.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,492.64 |
| Education | $29.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,520.52 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Janssen Biotech, INC. | $597.69 | 2020-2025 | Stelara, Tremfya, Simponi |
| Janssen Scientific Affairs, LLC | $354.04 | 2021-2022 | |
| Medtronic, INC. | $317.10 | 2024 | Signia |
| E.R. Squibb & Sons, L.L.C. | $235.79 | 2021 | |
| Mallinckrodt Hospital Products INC. | $176.79 | 2023-2025 | Terlivaz |
| Takeda Pharmaceuticals U.S.A., INC. | $173.23 | 2021-2025 | Gattex, Eohilia, Entyvio |
| Intercept Pharmaceuticals, INC. | $164.90 | 2021-2025 | Ocaliva |
| Phathom Pharmaceuticals, INC. | $139.99 | 2024-2025 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $125.00 | 2022 | |
| Novo Nordisk INC | $121.84 | 2025 | Wegovy |
| Endogastric Solutions, INC | $54.67 | 2024 | Esophyx |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $54.39 | 2019 | |
| Lilly USA, LLC | $31.86 | 2025 | Omvoh |
| Ardelyx, INC. | $31.63 | 2025 | Ibsrela |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $29.12 | 2024 | Zymfentra |
| Merck Sharp & Dohme LLC | $22.22 | 2024 | Dificid |
| Mirum Pharmaceuticals, INC. | $19.36 | 2025 | |
| Genzyme Corporation | $18.37 | 2024 | |
| Ferring Pharmaceuticals INC. | $17.50 | 2024 | Rebyota |
| Celgene Corporation | $17.25 | 2023 | Zeposia |
| Lucid Diagnostics INC. | $16.28 | 2022 | |
| Alnylam Pharmaceuticals INC. | $16.26 | 2024 | Givlaari |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Shue listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.